Tag Archives: Comparative Effectiveness

Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement

Between 1980 and 2010, overall personal health care expenditures in the US grew nearly four-fold, driven in part by new technologies. What---if anything---should be done to regulate this innovation?

September 15, 2016

The Power Of Four: Accelerating Interprofessional Collaboration In Nursing

Four foundations are funding an effort to help sixteen schools of nursing to create innovative, robust, and sustainable interprofessional education programs. The intended outcome is more effective patient care in community-based settings.

July 28, 2016

Takeaways From Our Twitter Chat With PCORI

Recently, we at Health Affairs hosted a Twitter chat with PCORI on the topic of patients' use of evidence. The chat was a follow-up to our "Patients' and Consumers' Use of Evidence" issue.

June 20, 2016

Is High Prescription Drug Spending Becoming Our New Normal?

Spending on specialty medicines was responsible for 73 percent of overall medicine spending growth over the past five years. It's time to stop viewing high priced drugs as isolated incidents, but rather we should consider what we can do about it.

May 17, 2016

How Government Policy Promotes High Drug Prices

US law governing prescription pharmaceutical markets gives every new drug a long-term monopoly that prohibits competition. High prices and slow innovation cycles are the inevitable result and will remain so unless Congress makes fundamental changes in existing law.

October 29, 2015

The Value And Limits Of Economic Evaluation In Policy Analysis

Health care resources, no matter how represented, are ultimately finite. In spite of this, U.S. policymakers remain reluctant to engage in conversations that even hint at “rationing,” evidenced by the fact that PCORI is legislatively forbidden to include cost-effectiveness ratios in its...

September 1, 2015

How Institutional Review Boards Can Support Learning Health Systems While Providing Meaningful Oversight

IRBs should educate themselves about quality improvement and comparative effectiveness research, exempt studies that qualify for exemption, and provide waivers to informed consent, when that is appropriate.

June 5, 2015

Health Affairs’ April Issue: The Cost And Quality Of Cancer Care

The April issue of Health Affairs contains a cluster of papers focusing on the cost and quality of cancer care. Other subjects covered in the issue: health care payment reform; the diminished number of uninsured young adults; and regulatory approval of new drugs by the FDA. Publication of...

April 6, 2015

Incorporating Cost-Effectiveness Analysis Into Comparative-Effectiveness Research: The French Experience

Editor’s note: This post is part of a series of several posts related to the 4th European Forum on Health Policy and Management: Innovation & Implementation, held in Berlin, Germany on January 29 and 30, 2015. For updates on the Forum’s results please check the Center for Healthcare...

April 3, 2015

Revisiting Mortality Versus Survival In International Comparisons Of Cancer Care

No one doubts that the US spends more than any other country on health care.  Whether this higher spending produces commensurate health benefits, however, is far from certain. In the April 2012 issue of Health Affairs, Philipson et. al. make an intuitively persuasive observation, one which...

April 1, 2015